Investegate |Erytech Pharma S.A. Announcements | Erytech Pharma S.A.: ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in ...